Detailed Characterization of the In Vitro Pharmacological and Pharmacokinetic Properties of N-(2-Hydroxybenzyl)-2,5-Dimethoxy-4-Cyanophenylethylamine (25CN-NBOH), a Highly Selective and Brain-Penetrant 5-HT2A Receptor Agonist

Therapeutic interest in augmentation of 5-hydroxytryptamine(2A) (5-HT2A) receptor signaling has been renewed by the effectiveness of psychedelic drugs in the treatment of various psychiatric conditions. In this study, we have further characterized the pharmacological properties of the recently developed 5-HT2 receptor agonist N-2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine (25CN-NBOH) and three structural analogs at recombinant 5-HT2A, 5-HT2B, and 5-HT2C receptors and investigated the pharmacokinetic properties of the compound. 25CN-NBOH displayed robust 5-HT2A selectivity in [H-3] ketanserin/[H-3] mesulergine, [H-3] lysergic acid diethylamide and [H-3] Cimbi-36 binding assays (K-i (2C)/K-i (2A) ratio range of 52-81; K-i (2B)/K-i (2A) ratio of 37). Moreover, in inositol phosphate and intracellular Ca2+ mobilization assays 25CN-NBOH exhibited 30-to 180-fold 5-HT2A/5-HT2C selectivities and 54-fold 5-HT2A/ 5-HT2B selectivity as measured by Dlog(Rmax/EC50) values. In an off-target screening 25CN-NBOH (10 mM) displayed either substantially weaker activity or inactivity at a plethora of other receptors, transporters, and kinases. In a toxicological screening, 25CN-NBOH(100 mu M) displayed a benign acute cellular toxicological profile. 25CN-NBOH displayed high in vitro permeability (P-app = 29 x 10(-6) cm/s) and low P-glycoprotein-mediated efflux in a conventional model of cellular transport barriers. In vivo, administration of 25CNNBOH (3 mg/kg, s. c.) in C57BL/6 mice mice produced plasma and brain concentrations of the free (unbound) compound of similar to 200 nM within 15 minutes, further supporting that 25CN-NBOH rapidly penetrates the blood-brain barrier and is not subjected to significant efflux. In conclusion, 25CN-NBOH appears to be a superior selective and brain-penetrant 5-HT2A receptor agonist compared with (+/-)-2,5-dimethoxy-4-iodoamphetamine (DOI), and thus we propose that the compound could be a valuable tool for future investigations of physiologic functions mediated by this receptor.